Cluenex
Log inStart free
All stocks · Healthcare · Life Sciences Tools & Services

IQVIA IQV

IQVIA scores weak on business quality (3.8 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$259.88Oct 9, 2026
Business qualityWeak
Next earningsOct 27, 2026, before the open
Insiders, 90 daysSelling

Why it matters

  1. What IQVIA does

    IQVIA provides clinical trial services, analytics, and healthcare data to pharmaceutical companies. Drug developers pay for research support and commercial execution.

  2. What it does best

    IQVIA runs clinical trials using an extensive proprietary database that few rivals can match. This data network helps sponsors find patients faster, though its gross margin sits at 33%, below peers like Danaher at 59%.

  3. The main risk

    Low liquidity and heavy debt pose pressing concerns. With interest coverage at 3.1x and net debt at $13.8 billion, rate shifts or operational hiccups strain the balance sheet significantly.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin stands at 13.9% with a net margin of 8.1%. While return on equity is strong at 22.0%, low gross margins mean scale does not translate into elite cash conversion.

MoatWeak

Its moat rests on massive healthcare data assets that lock in pharmaceutical clients. Yet a gross margin in the 16th sector percentile shows limited pricing power compared to peers.

GrowthSlow

Revenue grew 5.9% to $17.0B, continuing a steady climb from $11.4B in 2020. This rate remains modest within its sector, ranking in the 36th percentile for growth.

Financial healthWeak

Net debt sits at $13.8 billion with interest coverage at 3.1x, leaving little room for error. Free cash flow reached $2.2B, but the heavy debt load keeps the financial foundation soft.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

6 sold $29.9M outside pre-planned sales.

Our sealed record on IQV

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is IQV a good business?

IQVIA scores weak on the Cluenex quality check (3.8 of 10), measured against its own industry. Profitability is fair, moat weak, growth slow and financial health weak.

Are insiders buying IQV?

In the last 90 days of SEC Form 4 filings: 6 sold $29.9M outside pre-planned sales.

When does IQV report earnings?

Oct 27, 2026, before the open.

For members

See IQV today

  • Today's verdict on IQV, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “IQVIA (IQV)”, https://cluenex.com/stocks/iqv/, data as of Oct 10, 2026.